Since the cirrhotic livers have a nodular architecture with altered vascularity, which makes challenging the differentiation between regenerative nodules and HCC lesions in traditional imaging methods, this potential employment of PSMA-targeting radiopharmaceuticals needs to be further explored. The gene discussed is FOLH1; the disease is hepatocellular carcinoma.